Abdul Latif, Asnad, Abid Karim, Muhammad Ishaq, Israr Ahmed Akhund.
To Study Biochemical Effects of Optimized Product Ramipril 1.25mg Tablet with Essential Hypertension.
Med Forum Jan ;2(8):20-3.
Introduction: Hypertension is one of the strongest modifiable risk factors for cardiovascular and kidney disease and has been identified as the leading risk factor for mortality. The reduction of blood pressure lower than 130/85 mmHg provides additional benefits regarding both protection of organs and cardiovascular mortality. Angiotensin converting enzyme inhibitors have been shown to block the activation of the renin-angiotensin system in the plasma as well as in the vascular wall. Objective: The objective of this double-blind, comparative study evaluating the biochemical effects of optimized Ramipril 1.25mg tablet as monotherapy in adult patient with essential hypertension. Study Design: Double-blind, comparative study. Place and Duration of Study: This study was conducted at the Department of Biochemistry, University of Karachi from January 2011 to August 2011. Materials and Methods: This was multicenter randomized, double-blind, comparative study. Patients were randomized to receive Ramipril (1.25 mg) once daily for 8 weeks and at the end of study biochemical evaluation was done. Results: In the patients treated with optimized Ramipril 1.25mg tablets showed antihypertensive property. No significant variations of blood glucose and different parameters of lipid profile were observed during the eight weeks of treatment. Conclusion: We can suggest that the high antihypertensive efficacy, good tolerability and no biochemical effects of the optimized Ramipril 1.25mg (F-4) it is an excellent option for the treatment of hypertension in a wide range of hypertensive patients, with a high potential to reduce cardiovascular risks.
PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com